Immune checkpoint inhibitors have transformed the treatment algorithm for recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck (SCCHN) and diversified treatment options beyond standard Erbitux-based regimens. Merck & Co.’s Keytruda and Bristol-Myers Squibb’s Opdivo are already entrenched and good therapeutic options for previously treated recurrent or metastatic SCCHN. The 2019 label expansion of Merck & Co.’s Keytruda has revolutionized the choice of first-line therapy for SCCHN by offering better targeted therapeutic options with Keytruda regimens based on patient characteristics such as PD-L1 expression. The possibility of using immunotherapy with Keytruda frontline will shift current treatment practices.

Questions Answered

  • What are the drug-treatment rates in the clinically and commercially relevant SCCHN patient populations?
  • How are the immune checkpoint inhibitors performing in the face of existing and established therapies such as Erbitux and standard chemotherapy for recurrent or metastatic disease, according to U.S. medical oncologists?
  • What are the patient shares of key therapies used to treat locoregionally advanced non-nasopharyngeal SCCHN and recurrent or metastatic non-nasopharyngeal SCCHN in all lines of therapy?
  • What are the main drivers of and obstacles to prescribing current therapies for recurrent or metastatic non-nasopharyngeal SCCHN?

Product Description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Table of contents

  • Detailed, Expanded Analysis: Physician Insights (US)
    • Current Treatment: Physician Insights | Squamous Cell Carcinoma of the Head and Neck | US | March 2020

Author(s): Laura Vinuesa, DVM, MSc

Laura Vinuesa, DVM, is a Senior Business Insights Analyst in the Oncology Division at Decision Resources Group, with expertise in thyroid carcinoma and bladder cancer. Previously, Dr. Vinuesa was an EU Market Access Analyst in the Global Market Access Insights Team at Decision Resources Group. She has expertise in market access, pricing and reimbursement, health technology assessment, and health policy. Prior to joining Decision Resources, she worked as Market Access & Institutional Relations Analyst at Pfizer in Spain, providing support for the successful market launch of drugs for different areas: cardiovascular, oncology, mental disorder and rare disease. She is a Doctor of Veterinary Medicine from the Complutense University of Madrid, and holds a in Clinical Research and Pharmaceutical Medicine from EPHOS - School of PharmaStudies. lvinuesa@


Related Reports

Squamous Cell Carcinoma of the Head and Neck | Landscape & Forecast | Disease Landscape & Forecast

Treatment for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) has remained relatively unchanged in t...

View Details

Squamous Cell Carcinoma of the Head and Neck | Current Treatment | Detailed, Expanded Analysis (US): Treatment Sequencing

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.

View Details

Squamous Cell Carcinoma of the Head and Neck | Disease Landscape and Forecast | G7 | 2019

Market Outlook Treatment for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)...

View Details

Squamous Cell Carcinoma of the Head and Neck | Unmet Need | Detailed, Expanded Analysis: Recurrent or Metastatic Non-Nasopharyngeal SCCHN (US/EU)

Treatment of recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck (SCCHN) has remained relativ...

View Details